Company profile: Tevogen Bio
1.1 - Company Overview
Company description
- Provider of immunotherapy solutions focused on T cell therapies for infectious diseases, cancers, and neurological disorders. Offerings include the ExacTcell platform utilizing CD8+ cytotoxic T lymphocytes; TVGN 489, an investigational therapy for high-risk COVID-19 and potential Long COVID; Tevogen.AI to accelerate development and target detection; and the TCTL trial in adults with newly diagnosed COVID-19.
Products and services
- TVGN 489: Investigational T cell therapy targets high-risk COVID-19 patients and potentially Long COVID, employing a T lymphocyte approach for treatment and classified as investigational-grade
- ExacTcellTM Platform: Technology develops T cell therapies targeting infectious diseases, cancers, and neurological disorders by utilizing CD8+ cytotoxic T lymphocytes for immunotherapy development and designated as cell-based
- TCTL Trial: Study evaluates safety and efficacy of COVID-19-specific T cells in treating adult patients with newly diagnosed COVID-19 infection and operates as clinical-stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tevogen Bio
Leyden Labs
HQ: The Netherlands
Website
- Description: Provider of a mucosal immunity platform targeting commonalities of viral families to protect against known and future respiratory viruses, offering intranasal antibody sprays for immediate antiviral protection, including PanFlu nasal spray (CR9114 antibody) for broad influenza protection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leyden Labs company profile →
Sequella
HQ: United States
Website
- Description: Provider of biopharmaceutical products for diagnosing and treating epidemic infectious diseases, including SQ109 (Phase 2 for multidrug-resistant pulmonary tuberculosis), Sutezolid (oxazolidinone in clinical development for tuberculosis), SQ609 (preclinical for tuberculosis), SQ641 (preclinical for C. difficile and nontuberculous mycobacteria), B-SMART rapid TB susceptibility tests, and small-molecule and natural product drug discovery programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequella company profile →
OM Pharma
HQ: Switzerland
Website
- Description: Provider of microbial-derived immunotherapeutic products addressing acute and chronic immunological disorders from infections and inflammation, operating worldwide through partners and investing in R&D. Products include Broncho-Vaxom to regulate the immune system and prevent recurrent respiratory infections, Uro-Vaxom to treat and prevent recurrent lower urinary tract infections, and Dicynone for capillary hemorrhage prevention and treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OM Pharma company profile →
Lumora
HQ: United Kingdom
Website
- Description: Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumora company profile →
Okairos
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical discovery and development of genetic T-cell vaccines, including for hepatitis C virus, and health and allied services. Based in Basel, Switzerland, with operations in Rome and Naples, Italy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Okairos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tevogen Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tevogen Bio
2.2 - Growth funds investing in similar companies to Tevogen Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tevogen Bio
4.2 - Public trading comparable groups for Tevogen Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →